Mark Kidd
Overview
Explore the profile of Mark Kidd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
6345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rahbar K, Kidd M, Prasad V, Rosin R, Drozdov I, Halim A
Prostate
. 2025 Jan;
e24858.
PMID: 39838708
Introduction: Prostate cancer (PCa) is the most commonly diagnosed cancer in men in the United States, following skin cancer, with an incidence rate of 112.7 per 100,000 men per year....
2.
Rosin R, Haynes A, Kidd M, Drozdov I, Modlin I, Halim A
Cancer Epidemiol
. 2024 Aug;
92:102642.
PMID: 39121520
Introduction: The PROSTest is a novel machine learning-based liquid biopsy assay that functions as a diagnostic and prognostic tool in prostate cancer (PCa). The algorithm outcome (scored 0-100) has a...
3.
Modlin I, Kidd M, Drozdov I, Boegemann M, Bodei L, Kunikowska J, et al.
Prostate
. 2024 Apr;
84(9):850-865.
PMID: 38571290
Introduction: We describe the development of a molecular assay from publicly available tumor tissue mRNA databases using machine learning and present preliminary evidence of functionality as a diagnostic and monitoring...
4.
Yang J, Kidd M, Nordquist A, Smith S, Hurth C, Modlin I, et al.
Infect Dis Rep
. 2021 Dec;
13(4):1061-1077.
PMID: 34940407
Since the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in December 2019, the spread of SARS-CoV2 infection has been escalating rapidly around the world. In order...
5.
Pacak K, Kidd M, Meuter L, Modlin I
Endocr Relat Cancer
. 2021 Sep;
28(11):731-744.
PMID: 34515661
Pheochromocytomas and paragangliomas (PHEOs/PGLs) represent diagnostically challenging and complex neuroendocrine tumors (NETs). Current biomarker tests for PHEOs/PGLs are technically complex or limited. We assessed the diagnostic utility of a NET-specific...
6.
Modlin I, Kidd M, Frilling A, Falconi M, Filosso P, Malczewska A, et al.
Ann Surg
. 2021 Jun;
274(3):481-490.
PMID: 34183517
Introduction: Identification of residual disease after neuroendocrine tumor (NET) resection is critical for management. Post-surgery imaging is insensitive, expensive, and current biomarkers ineffective. We evaluated whether the NETest, a multigene...
7.
Modlin I, Kidd M, Oberg K, Falconi M, Filosso P, Frilling A, et al.
Ann Surg Oncol
. 2021 May;
28(12):7506-7517.
PMID: 34008138
Introduction: Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management, but...
8.
Frilling A, Clift A, Frampton A, Bomanji J, Kaemmerer D, Al-Nahhas A, et al.
Int J Med Sci
. 2021 Apr;
18(10):2166-2175.
PMID: 33859524
Neuroendocrine neoplasia (NEN) of small bowel (SBNEN) frequently present with metastatic disease. Theranostics (molecular imaging followed by targeting therapy) allow for personalised medicine. Liquid biopsies enable precise identification of residual...
9.
Rinke A, Auernhammer C, Bodei L, Kidd M, Krug S, Lawlor R, et al.
Gut
. 2021 Mar;
70(9):1768-1781.
PMID: 33692095
Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby...
10.
Kidd M, Kitz A, Drozdov I, Modlin I
Neuroendocrinology
. 2020 May;
111(5):490-504.
PMID: 32392558
Background: The NETest is a multigene assay comprising 51 circulating neuroendocrine tumor (NET)-specific transcripts. The quotient of the 51-gene assay is based upon an ensemble of machine learning algorithms. Eight...